Skip to main content
. Author manuscript; available in PMC: 2024 Jul 30.
Published in final edited form as: FASEB J. 2022 Jun;36(6):e22335. doi: 10.1096/fj.202101518R

FIGURE 1. SIRT6 is a target of TGF-β signaling.

FIGURE 1.

(A) Schematic of the human SIRT6 promoter with potential SBEs and CTCF binding sites. (B) Representative SMAD3 and CTCF binding peaks at the SIRT6 promoter and enhancer regions from one of three ChIP-Seq experiments in HepG2 cells with or without TGF-β treatment. The region of chromosome 19 (chr19) is indicated. (C) SMAD3 binding to SBE1 and SBE2 from ChIP-qPCR experiments is presented as the fold recruitment. Data are presented as the mean ± SEM of three independent experiments. *, p < 0.05; compared with IgG group. (D) Relative mRNA levels of SIRT6 and SERPINE1 were determined in MEFs exposed to 200 pM TGF-β for 24 h. *, p < 0.05; compared to WT. (E) SIRT6 was detected by Western blotting in MEFs with different genotyping (left) and HepG2 stable cell lines with or without SMAD3 knockdown (right). GAPDH or ACTIN served as the loading control.